Denver—Many good strategies for prophylaxis and treatment of invasive fungal infections (IFI) in cancer patients will not be found in books, several experts stressed during presentations at the 2018 annual meeting of the Hematology/Oncology Pharmacy Association (HOPA).
The recurring messages were that IFI data can be complicated and the new, expensive broad-spectrum antifungal agent will not necessarily get clinicians out of trouble when they are managing patients undergoing